

What every Hepatologist should Know about Swine Flu?

Kamran Bagheri Lankarani

Health Policy Research Center and Gastroenterology and Hepatology Research Center,
Shiraz University of Medical Sciences, Shiraz, I.R. Iran
lankaran@sums.ac.ir

As world is witnessing ever fastest growing pandemic, physicians with various specialties should adopt themselves to the new situation ⁽¹⁾. Global death toll of swine flu by November 15, 2009, has raised to 6750. Many of those who died or were hospitalized suffered from comorbid conditions which increased either the severity or the risk of acquiring the disease ⁽²⁾. Swine flu may change the course of many chronic diseases. Thus, all physicians in different disciplines should realize and consider the impact of the current pandemic on their daily practice.

As the new pandemic flu virus 2009 (H1N1) has been circulating only in the past nine months, there is still not much evidence on the interaction of this pandemic with chronic diseases. However, presumably, much of this interaction is expected to be similar to other circulating influenza type A viruses. But there are clear differences with the current pandemic, for example, near one-third of severe cases had no underlying conditions and their median age was much lower than the usual seasonal flu ⁽³⁾.

Hepatologists caring for both acute and chronic liver diseases anywhere in the world would probably see much about this interaction in upcoming months and even years. In this review, we tried to somehow classify our current knowledge on possible interactions between swine flu and various liver diseases. Much of the described effects are from the older evidence mostly related to influenza type A, and as was mentioned before, with expansion of the current pandemic and growing our knowledge about the nature of this new virus, these suggestions might be changed later on.

Liver damage by flu virus

Liver damage with influenza virus has been shown in animal models. Indeed, the mouse/influenza B virus is a well-established model for Reye's syndrome with a histological picture resembling human disease including microvesicular steatosis and minimal inflammation ⁽⁴⁾. The primary infected cells in these animals are hepatocytes with minimal infection of the Kupffer cells ⁽⁵⁾. The liver parenchyma infection in mouse model is abortive or non-permissive characterized by the absence of viral replication in the liver and brain and absence of complete viral particles on electron microscopy, despite the presence of viral antigens within the hepatocytes and minimal inflammation in biopsied specimens ⁽⁶⁾.

At least, in animal models the liver damage could be seen even in the absence of virus isolation from the liver. Circulating cytokines and chemokines may contribute to liver damage. Derangement of lipid metabolism secondary to depressed mitochondrial enzyme activities and mitochondrial structural damage is probably a critical step in hepatic damage in flu infection ⁽⁷⁾. Polakos *et al.* have recently reported the so called collateral damage of liver with influenza virus. They found that in the absence of viral antigen in the liver, hepatocytes could be damaged by viral specific CD8⁺ T cells generated outside of liver for example in the lungs. In their series of 15 volunteers infected with H1N1 influenza virus, four patients developed liver enzyme elevation up to three times the upper limit of normal. Interestingly, this enzyme raise occurred when the fever was stopped indicating that the process is not related to direct viral replication ⁽⁸⁾.

Till 1980's, the most common hepatic manifestation of flu in children was considered to be Reye's syndrome⁽⁹⁾. Realizing the association of this dreadful complication of influenza-like illness (ILI) and aspirin ingestion, lead to a sharp decline in the incidence of this syndrome⁽¹⁰⁾. The importance of this association in the current pandemic, however, could not be overemphasized. Pediatric patients on chronic aspirin treatment such as those with rheumatologic diseases are at increased risk of this syndrome during the pandemic⁽¹¹⁾. These patients probably need to be prioritized for flu vaccination and should discontinue their aspirin intake upon development of ILI.

In rare instances, flu virus may cause acute hepatic failure. The probability of causing such a complication may differ between subtypes of influenza virus⁽¹²⁾. Nevertheless, so far we do not have any data on the incidence of this complication with the new pandemic H1N1 virus. Reported death with the new virus was not accompanied with liver failure, so probably this complication is not common with this new virus.

Interaction of flu and chronic liver disease

Flu may increase the risk of decompensation in cirrhotic patients⁽¹³⁾. This could be attributed to direct hepatic damage by the flu virus or due to cytokines/chemokines-induced damage during systemic infection⁽¹⁴⁾. Risk of both acquiring the disease and developing severe form of the disease may be increased in these patients. In the meantime, concomitant pleural effusion, decreased lung compliance, hepatopulmonary syndrome and portopulmonary hypertension may also contribute to make the disease more severe⁽¹⁵⁾.

This disease may have a higher mortality rate in immunosuppressed patients. Example of such patients are those with chronic liver disease, especially those suffering from autoimmune liver disease and liver transplant recipients who use immunosuppressive drugs.

Corticosteroids in doses higher than 10 mg per day or a cumulative dose of more than 700 mg predisposes the patient to a variety of infections including influenza⁽¹⁶⁾. Systemic corticosteroids may also increase the risk of hospitalization and death among patients with flu⁽¹⁷⁾. Corticosteroids in hepatology clinics are used usually in combination with immunosuppressants which may potentiate its detrimental effects on flu infection. Disease flare up has not been reported in rheumatologic patients receiving steroids, after acquiring flu. However, data

on patients with liver disease taking steroids is not clear.

It is not known whether the risk of infection among patients receiving immunosuppressive drugs is higher but infection in these patients usually has a longer duration with more virus shedding and more chance of antiviral resistance⁽¹⁷⁾.

In pediatric patients receiving solid organ transplantation including liver, the influenza virus infection is more severe, has higher hospitalization rate, has more need for mechanical ventilation and more chance of death⁽¹⁸⁾. Apalsch *et al.* reported that the risk factors for death among pediatric solid transplant recipients with flu are younger age of recipient (<6 month), early post-transplant period (<1 month) and increased dose of immunosuppressive agents⁽¹⁹⁾.

The disease course in adults is more variable. A report from Sweden indicated that the course of influenza A in renal and bone marrow transplant recipients was usually mild and self-limited, although occasional severe cases also occurred⁽²⁰⁾. This variability may be related to the amount of immunosuppression and the time from transplantation.

Infection, itself, provokes rejection in kidney transplant patients but this observation has not been proven for liver transplantation⁽²¹⁾. Most of these reports came from the time when cyclosporine and other potent immunosuppressives were not available. Presence of such association has not been proved with the current immunosuppressive armamentarium.

Obesity and diabetes mellitus are two of the most common risk factors for fatality in the new pandemic flu in those aged 20 years and older⁽²²⁾. In a recent series from California, USA, the rate of obesity was 50% in hospitalized patients with the new H1N1 pandemic influenza (2009); a quarter of which being morbid obese. In one-third of hospitalized patients, obesity was the only risk factor⁽²³⁾. The association of obesity with non-alcoholic steatohepatitis (NASH) nowadays, has brought many of obese patients under follow-up of hepatologists. The higher complication rate of the new pandemic flu should alert hepatologists when taking care for these patients and any signs of ILI should be taken seriously and appropriate referral should be done in a timely manner.

Treatment of swine flu in patients with chronic liver disease

Available treatments for swine flu include neuraminidase inhibitors (*e.g.*, oseltamivir and zanamivir). Whether these drugs need dose adjustment in patients with hepatic failure is not

known. There are case reports of prolonged virus shedding and development of viral resistance in immunocompromised hosts receiving these antiviral agents (24).

Flu vaccine in chronic liver disease patients

There is concern about the effectiveness of vaccines in immunosuppressed patients. A diminished antibody response has been reported in liver transplant recipients after receiving influenza vaccine (25). This lower antibody response depends on the type of immunosuppressant drug with much lower antibody response in those receiving mycophenolate mofetil or cyclosporine compared to drugs such as azathioprine. The lowest response has been reported with mycophenolate mofetil (26). The current data did not show any difference between tacrolimus and either of cyclosporine or sirolimus. Previous recommendation advised yearly seasonal flu vaccination for all of solid organ transplant recipients six months after transplantation (27). This recommendation was based on this assumption that in most cases of solid organ transplantation, by this time, the dose of immunosuppressive drugs has been reduced and stabilized so that there would probably be a higher antibody response. There is a theoretical concern that vaccination in these patients may evoke a T cell response leading to rejection (28). The association of flu shot and rejection has not been shown in liver transplantation but there are contradictory reports on subclinical rejection in heart transplant patients receiving flu vaccine (29). Based on these assumptions, delaying vaccination for six months was proposed in past. Currently, this recommendation may need some modifications, but there are no solid evidence indicating the exact timing of vaccination in this special group of patients. In post-liver transplantation patients, only 68% of flu vaccine recipients developed protective levels of antibody with a single shot of the vaccine. A second dose, inoculated one month later, increased the rate of antibody response to 80% (30). Therefore, it is quite reasonable to schedule these patients to receive two shots from the beginning.

Vaccination of patients in waiting list for liver transplantation and probably all patients with chronic liver disease, especially those who are on immunosuppressive drugs or with cirrhosis, should also be prioritized.

As infection could spread from medical staff caring for these patients to them, even from asymptomatic or minimally symptomatic personnel, vaccination of these staff should also be done.

Antibody response to flu vaccine may be lower

in patients on chronic steroid therapy depending on the dose, duration of the treatment, the underlying disease and use of immunosuppressant drugs (31).

No harmful event has been reported with use of live attenuated flu vaccine in patients on immunosuppressive and or corticosteroid therapy. Nonetheless, current data do not support the use of live attenuated vaccine, especially in transplant patients and those on immunosuppressive drugs; it is safer to use inactivated viral vaccines in these particular group of patients (32).

Data on the safety and efficacy of live attenuated flu vaccine in cirrhotic patients is not conclusive but the effect is probably not much different from healthy individuals, as long as the patient is not on immunosuppressive drugs or malnourished.

Antibody response in these patients depends on other factors including age, with least response in those less than one month old or older than 65 years (33).

Conclusions

As the current pandemic of new H1N1 virus is progressing, hepatologists should realize and consider the potential effects of this infection on patients with chronic liver disease. These patients, especially those on immunosuppressive agents and transplantation recipients should be prioritized for vaccination, preferably with an inactivated vaccine. The course of flu in these patients may be more severe. Obese patients with NASH should receive particular attention in this regard. Deterioration of hepatic function in patients with stable liver disease might be caused by flu. These patients may benefit from early diagnosis and treatment.

Acknowledgements

The editorial assistance by Dr. Sabayan and Miss Sedaghat both from Health Policy Research Center in preparation of this manuscript is appreciated.

References

1. Schout D, Hajjar LA, Galas FR, *et al.* Epidemiology of human infection with the novel virus influenza A (H1N1) in the Hospital das Clinicas, Sao Paulo, Brazil--June-September 2009. *Clinics (Sao Paulo)*. 2009;64(10):1025-30.
2. Vaillant L, La Ruche G, Tarantola A, Barboza P. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. *Euro Surveill*. 2009;14(33).
3. Intensive-care patients with severe novel influenza A (H1N1) virus infection - Michigan, June 2009. *MMWR Morb*

- Mortal Wkly Rep.* 2009;**58**(27):749-52.
4. Davis LE, Kornfeld M. Mouse influenza B virus model of Reye's syndrome. Encephalopathy and microvesicular fatty metamorphosis of the liver by influenza B virus following intravenous administration in mice. *Am J Pathol.* 1986;**122**(1):190-2.
 5. Adams DH, Hubscher SG. Systemic viral infections and collateral damage in the liver. *Am J Pathol.* 2006;**168**(4):1057-9.
 6. Fislova T, Gocnik M, Sladkova T, et al. Multiorgan distribution of human influenza A virus strains observed in a mouse model. *Arch Virol.* 2009;**154**(3):409-19.
 7. Woodfin BM, Kazim AL. Interaction of the amino-terminus of an influenza virus protein with mitochondria. *Arch Biochem Biophys.* 1993;**306**(2):427-30.
 8. Polakos NK, Cornejo JC, Murray DA, et al. Kupffer cell-dependent hepatitis occurs during influenza infection. *Am J Pathol.* 2006;**168**(4):1169-78; quiz 404-5.
 9. Monto AS. The disappearance of Reye's syndrome--a public health triumph. *N Engl J Med.* 1999;**340**(18):1423-4.
 10. Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB. Reye's syndrome in the United States from 1981 through 1997. *N Engl J Med.* 1999;**340**(18):1377-82.
 11. Wood LE, Tulloh RM. Kawasaki disease in children. *Heart.* 2009;**95**(10):787-92.
 12. Stanley TV. Acute liver failure following influenza B infection. *N Z Med J.* 1994;**107**(986 Pt 1):382.
 13. Duchini A, Hendry RM, Redfield DC, Pockros PJ. Influenza infection in patients before and after liver transplantation. *Liver Transpl.* 2000;**6**(5):531-42.
 14. Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. *J Hepatol.* 2004;**40**(5):823-30.
 15. Cheruvattath R, Balan V. Infections in Patients With End-stage Liver Disease. *J Clin Gastroenterol.* 2007;**41**(4):403-11.
 16. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. *Rev Infect Dis.* 1989;**11**(6):954-63.
 17. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. *Lancet Infect Dis.* 2009;**9**(8):493-504.
 18. Blumberg EA, Albano C, Pruett T, et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. *Clin Infect Dis.* 1996;**22**(2):295-302.
 19. Duchini A, Hendry RM, Nyberg LM, Viernes ME, Pockros PJ. Immune response to influenza vaccine in adult liver transplant recipients. *Liver Transpl.* 2001;**7**(4):311-3.
 20. Ljungman P, Andersson J, Aschan J, et al. Influenza A in immunocompromised patients. *Clin Infect Dis.* 1993;**17**(2):244-7.
 21. Soesman NM, Rimmelzwaan GF, Nieuwkoop NJ, et al. Efficacy of influenza vaccination in adult liver transplant recipients. *J Med Virol.* 2000;**61**(1):85-93.
 22. Rothberg MB, Haessler SD. Complications of seasonal and pandemic influenza. *Crit Care Med.* 2009.
 23. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. *JAMA.* 2009;**302**(17):1896-902.
 24. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. *J Infect Dis.* 1998;**178**(5):1257-62.
 25. Hayney MS, Welter DL, Francois M, Reynolds AM, Love RB. Influenza vaccine antibody responses in lung transplant recipients. *Prog Transplant.* 2004;**14**(4):346-51.
 26. Smith KG, Isbel NM, Catton MG, Leydon JA, Becker GJ, Walker RG. Suppression of the humoral immune response by mycophenolate mofetil. *Nephrol Dial Transplant.* 1998;**13**(1):160-4.
 27. Guidelines for vaccination of solid organ transplant candidates and recipients. *Am J Transplant.* 2004;**4** Suppl 10:160-3.
 28. Mazzone PJ, Mossad SB, Mawhorter SD, Mehta AC, Mauer JR. Cell-mediated immune response to influenza vaccination in lung transplant recipients. *J Heart Lung Transplant.* 2004;**23**(10):1175-81.
 29. White-Williams C, Brown R, Kirklín J, et al. Improving clinical practice: should we give influenza vaccinations to heart transplant patients? *J Heart Lung Transplant.* 2006;**25**(3):320-3.
 30. Chesi C, Gunther M, Huzly D, et al. Immunization of liver and renal transplant recipients: a seroepidemiological and sociodemographic survey. *Transpl Infect Dis.* 2009.
 31. Hanania NA, Sockrider M, Castro M, et al. Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy. *J Allergy Clin Immunol.* 2004;**113**(4):717-24.
 32. Madan RP, Tan M, Fernandez-Sesma A, et al. A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings. *Clin Infect Dis.* 2008;**46**(5):712-8.
 33. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. *J Infect Dis.* 2009;**200**(2):172-80.